The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma - PubMed (original) (raw)

Case Reports

The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma

I S Mackenzie et al. Eur J Endocrinol. 2007 Oct.

Abstract

123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy scanning is commonly used in the imaging of phaeochromocytoma (and paraganglioma) to confirm the site of disease and whether any spread has occurred. However, 123I-MIBG imaging is negative in 15% of cases of benign phaeochromocytoma and around 50% of cases of malignant phaeochromocytoma. In recent years, positron emission tomography (PET) scanning using various different radiotracers has been shown to be a good alternative or supplementary investigation in phaeochromocytoma. We present the cases of four patients with symptoms and signs suggestive of phaeochromocytoma, but who had negative 123I-MIBG scans, and illustrate the usefulness of 18-fluoro-dihydroxyphenylalanine PET scanning in their assessment. In one of the patients, we illustrate how fluorodeoxyglucose PETscanning can provide useful information about the extent of malignant disease. These illustrative cases lend further support for the use of PET scanning in the assessment of phaeochromocytoma and suggest that it may have a particularly important role in the investigation of patients in whom 123I-MIBG scanning is negative.

PubMed Disclaimer

Cited by

A Case of 123I-Metaiodobenzylguanidine Scintigraphy-Negative Pheochromocytoma with a Tumor-Developing Mutation in the RET Gene.
Kubo H, Tsurutani Y, Sunouchi T, Hoshino Y, Hirose R, Katsuragawa S, Kimura N, Saito J, Nishikawa T. Kubo H, et al. J Clin Med. 2022 Aug 8;11(15):4624. doi: 10.3390/jcm11154624. J Clin Med. 2022. PMID: 35956242 Free PMC article.
A case of (123)I-MIBG scintigram-negative functioning pheochromocytoma: immunohistochemical and molecular analysis with review of literature.
Kurisaki-Arakawa A, Saito T, Takahashi M, Mitani K, Yao T. Kurisaki-Arakawa A, et al. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4438-47. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25120831 Free PMC article. Review.
The genetic basis of pheochromocytoma and paraganglioma: implications for management.
Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM. Shuch B, et al. Urology. 2014 Jun;83(6):1225-32. doi: 10.1016/j.urology.2014.01.007. Epub 2014 Mar 15. Urology. 2014. PMID: 24642075 Free PMC article. Review.
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.
Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC, de Krijger RR, Chiti A, Al-Nahhas A, Pacak K, Rubello D; European Association of Nuclear Medicine. Taïeb D, et al. Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1977-95. doi: 10.1007/s00259-012-2215-8. Epub 2012 Aug 28. Eur J Nucl Med Mol Imaging. 2012. PMID: 22926712 Free PMC article.
Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis.
Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, Rufini V, Giordano A. Treglia G, et al. Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1144-53. doi: 10.1007/s00259-012-2087-y. Epub 2012 Feb 23. Eur J Nucl Med Mol Imaging. 2012. PMID: 22358431 Review.

The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma - PubMed (original) (raw)